AR and glycogen storage disease VI: Prospectively, the genomic analysis of prostate CTCs for the androgen receptor splice variant, AR-V7, could serve as a predictive tool for assessing the clinical benefits of enzalutamide or abiraterone in terms of prostatic surface antigen (PSA) and imaging responses, within the context of metastatic castration-resistant disease.